Pharmacokinetics of cefquinome in rainbow trout (Oncorhynchus mykiss) after intravascular, intraperitoneal, and oral administrations. Issue 6 (24th August 2022)

• Record Type: Journal Article
• Authors: Durna Corum, Duygu; Corum, Orhan; Terzi, Ertugrul; Coskun, Devran; Bilen, Soner; Cetin, Gul; Uney, Kamil
• Is Part Of: Journal of veterinary pharmacology and therapeutics. Volume 45:Issue 6(2022)
• Page Start: 578
• Page End: 583
• Publication Date: 2022-08-24
• Subjects: bioavailability -- cefquinome -- pharmacokinetics -- rainbow trout; Veterinary pharmacology -- Periodicals; Therapeutics -- Periodicals; 636.0895105
• DOI: 10.1111/jvp.13091
• Languages: English
• ISSNs: 0140-7783

Abstract

Abstract: This study aimed to determine the pharmacokinetics and bioavailability of cefquinome in rainbow trout ( Oncorhynchus mykiss ) following intravascular (IV), intraperitoneal (IP), and oral (PO) administrations at 14 ± 1°C. In this study, three hundred and six clinically healthy rainbow trout (110–140 g) were used. The fish received single IV, IP, and PO injections of cefquinome at 10 mg/kg dose. The plasma concentrations of cefquinome were measured using HPLC‐UV and were evaluated using non‐compartmental analysis. Cefquinome was measured up to 96 h for PO route and 144 h for IV and IP routes in plasma. Following IV administration, t1/2ʎz, ClT, and Vdss were 18.85 h, 0.037 L/h/kg, and 0.84 L/kg, respectively. The Cmax of IP and PO routes was 9.75 and 1.64 μg/ml, respectively. The bioavailability following IP and PO administrations was 59.46% and 12.33%, respectively. Cefquinome at 10 mg/kg dose may maintain T > MIC above 40% at 72 and 96 h intervals, respectively, following the IP and IV routes for bacteria with MIC values of ≤2 μg/ml and at 24 h intervals following the PO route for bacteria with MIC value of ≤0.75 μg/ml. However, further studies are needed to determine in vitro and in vivo antibacterial efficacy and multiple dosage regimens of cefquinome against pathogens isolated from rainbow trout.